SCHEMBL4848384

SCHEMBL4848384

CCc1nc(CP(=O)(O)O)c(C)s1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGK1 P00558 4/20 0.32
PGK2 P07205 4/20 0.32
NPC1 O15118 4/20 0.32
RAB9A P51151 4/20 0.32
GAA P10253 1/20 0.32
MAPK1 P28482 1/20 0.32
FBP1 P09467 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
POLB P06746 2/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
ALOX15 P16050 1/20 0.32
TSHR P16473 1/20 0.32
OPRK1 P41145 1/20 0.32
HTT P42858 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
FDPS P14324 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14283763 0.76 NOS1 (0.42) PGK1PGK2GAAMAPK1FBP1
SCHEMBL4846912 0.75 GAA (0.42) NPC1RAB9AGAAMAPK1POLB
SCHEMBL4849195 0.68 DNM1L (0.45) NPC1RAB9AGAAMAPK1SMN1; SMN2
SCHEMBL11315669 0.67 KDM4E (0.36) KDM4EALDH1A1L3MBTL1
SCHEMBL4851509 0.66 ALDH1A1 (0.50) NPC1RAB9AGAASMN1; SMN2KDM4E
SCHEMBL4848422 0.64 PGK1 (0.44) PGK1PGK2FDPS
SCHEMBL6502840 0.64 HCAR2 (0.39) NPC1RAB9AGAAMAPK1SMN1; SMN2
SCHEMBL13533946 0.63 RECQL (0.34) L3MBTL1
SCHEMBL18676025 0.62
SCHEMBL17428909 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368578-B2 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-05-06 US disclosed
US-20060135578-A1 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-22 US disclosed
EP-1541564-A1 FIVE-MEMBERED HETEROCYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135578-A1 Five-membered heterocyclic compounds GPR119, OR10J3, CYP11B1 PGK1 3240/4885PGK2 3966/4885NPC1 822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.